|By Business Wire||
|August 4, 2014 09:01 AM EDT||
Life science market intelligence company, Evaluate, Ltd., announced today that Founder and CEO, Dr. Jonathan de Pass, has been selected by PharmaVOICE magazine as one of the top 100 most inspirational and influential people in the Life Sciences Industry.
The PharmaVOICE 100 represents leaders from across the global life sciences industry. A panel of PharmaVOICE editors chose the winners based on their ability to inspire, motivate and influence corporate leadership, research and development, technology, creativity and marketing and strategy.
Dr. de Pass founded Evaluate, Ltd. and the EvaluatePharma service from the ground up in 1996. Since then, Evaluate has come to be regarded as a trusted leader in life science market intelligence, known for its expertise, creativity and customer service by most of the world’s global pharmaceutical companies. A career highlight for Dr. de Pass was winning the Queens Award for Enterprise in 2009, one of the UK’s most prestigious business awards.
“For the 10 years I have worked with Jonathan, he has not only motivated me to always improve the way we manage and grow our services but has been an excellent person to work alongside, learn from and most importantly be inspired by,” said Debbie Paul, CEO, EvaluatePharma USA, Inc.
To read the 2014 PharmaVOICE 100 profiles, visit www.pharmavoice.com.
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.
Sep. 2, 2015 04:00 AM EDT Reads: 232
Sep. 2, 2015 04:00 AM EDT Reads: 477
Sep. 2, 2015 03:45 AM EDT Reads: 423
Sep. 2, 2015 03:30 AM EDT Reads: 603
Sep. 2, 2015 03:00 AM EDT Reads: 520
Sep. 2, 2015 02:30 AM EDT Reads: 445
Sep. 2, 2015 02:00 AM EDT Reads: 694
Sep. 2, 2015 01:45 AM EDT Reads: 480
Sep. 1, 2015 11:45 PM EDT Reads: 396
Sep. 1, 2015 11:45 PM EDT Reads: 541
Sep. 1, 2015 11:00 PM EDT Reads: 510
Sep. 1, 2015 07:00 PM EDT Reads: 273
Sep. 1, 2015 04:30 PM EDT Reads: 392
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
Sep. 1, 2015 04:00 PM EDT Reads: 216
Sep. 1, 2015 04:00 PM EDT Reads: 200